Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.00
+0.06 (0.86%)
At close: Mar 9, 2026, 4:00 PM EDT
7.00
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Kezar Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | 7 | - | - | - | |
| Cost of Revenue | 44.71 | 65.74 | 85.7 | 51.01 | 38.94 | - | |
| Gross Profit | -44.71 | -65.74 | -78.7 | -51.01 | -38.94 | - | |
| Selling, General & Admin | 20.81 | 23.39 | 26.54 | 20.15 | 15.72 | 11.97 | |
| Research & Development | - | - | - | - | - | 30.98 | |
| Operating Expenses | 20.79 | 23.39 | 26.54 | 20.15 | 15.72 | 42.95 | |
| Operating Income | -65.5 | -89.14 | -105.24 | -71.16 | -54.66 | -42.95 | |
| Interest Expense | -1.59 | -1.59 | -1.55 | -1.19 | -0.16 | - | |
| Interest & Investment Income | 5.38 | 8.46 | 11.1 | 4.11 | 0.19 | 1.21 | |
| EBT Excluding Unusual Items | -61.72 | -82.27 | -95.68 | -68.24 | -54.63 | -41.74 | |
| Merger & Restructuring Charges | 0.01 | -1.47 | -6.19 | - | - | - | |
| Pretax Income | -61.71 | -83.74 | -101.87 | -68.24 | -54.63 | -41.74 | |
| Net Income | -61.71 | -83.74 | -101.87 | -68.24 | -54.63 | -41.74 | |
| Net Income to Common | -61.71 | -83.74 | -101.87 | -68.24 | -54.63 | -41.74 | |
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 5 | 4 | |
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 5 | 4 | |
| Shares Change (YoY) | 0.36% | 0.48% | 7.70% | 27.69% | 19.90% | 130.58% | |
| EPS (Basic) | -8.44 | -11.49 | -14.04 | -10.13 | -10.35 | -9.49 | |
| EPS (Diluted) | -8.44 | -11.49 | -14.04 | -10.13 | -10.35 | -9.49 | |
| Free Cash Flow | -56.66 | -74.24 | -83.46 | -60.42 | -42.75 | -37.14 | |
| Free Cash Flow Per Share | -7.75 | -10.18 | -11.50 | -8.97 | -8.10 | -8.44 | |
| Operating Margin | - | - | -1503.39% | - | - | - | |
| Profit Margin | - | - | -1455.29% | - | - | - | |
| Free Cash Flow Margin | - | - | -1192.21% | - | - | - | |
| EBITDA | -64.52 | -88.1 | -104.17 | -70.14 | -53.15 | -41.41 | |
| D&A For EBITDA | 0.98 | 1.04 | 1.07 | 1.02 | 1.51 | 1.54 | |
| EBIT | -65.5 | -89.14 | -105.24 | -71.16 | -54.66 | -42.95 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.